内科

【摘要】目的探讨噻托溴铵联合丙酸倍氯米松治疗慢性阻塞性肺疾病患者的疗效以及对患者肺功能的影响。方法选取本院呼吸内科收治的COPD患者80例，随机均分为观察组和对照组。对照组患者接受抗感染、解痉平喘、吸氧等常规治疗；观察组患者在对照组治疗的基础上加用噻托溴铵联合丙酸倍氯米松吸入治疗，疗程8周。比较两组患者治疗前后的肺功能、呼吸困难（mMRC量表）情况及临床疗效。结果治疗8周后，两组患者的FEV1、PEF、FEV1/FVC均得到改善（P＜0.05），观察组患者改善情况优于对照组（P＜0.01）；观察组患者的mMRC评分低于对照组（P＜0.01）；观察组患者的治疗总有效率（92.5%）高于对照组的（72.5%），临床疗效优于对照组（P＜0.05）。结论在常规治疗的基础上，噻托溴铵联合丙酸倍氯米松吸入治疗COPD患者临床效果显著，能显著改善患者肺功能及呼吸困难症状，值得推广应用。

【Abstract】ObjectiveTo explore the effect of tiotropium bromide combined with beconase in COPD patients and its effect on pulmonary function. MethodsA total of 80 cases of COPD patients were enrolled in our department of respiratory medicine, which randomly divided into two groups. The control group received conventional treatment such as antiinfection, antispasmodic, antiasthmatic and oxygen inhalation, and on the basis of this, the observation group were treated with tiotropium bromide combined with beconase which were treated with aerosolized for 8 weeks. The lung function, modified medical research council (MMRC) and clinical efficacy were compared between the two groups before and after treatment. ResultsThe FEV1, PEF, FEV1/FVC in the two groups were improved after 8 weeks treatment(P＜0.05), and the observation group is better than that of the control group（P＜0.01）. The MMRC score of the observation group was lower than that of the control group (P＜0.01). The total effective rate of the observation group (92.5%) was higher than that of the control group (72.5%), and the clinical efficacy of the observation group was better than that of the control group (P＜0.05). ConclusionTiotropium bromide combined with beconase can significantly enhance COPD patients′ clinical efficacy on the basis of the routine treatment. Improve the patients′ lung function and dyspnea symptoms. It is worthy of promotion and application.